Trial Profile
An open-label study comparing a steroid sparing versus a standard steroid regimen in combination with CellCept [mycophenolate mofetil], Zenapax [daclizumab] and sirolimus in the prevention of acute renal allograft rejection
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary) ; Mycophenolate mofetil; Prednisolone; Sirolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Roche
- 07 Apr 2022 This trial has been completed in Spain (End Date: 11 Jul 2006), according to European Clinical Trials Database record.
- 23 Feb 2010 Actual initiation date (Apr 2006) added as reported by Roche record.
- 23 Mar 2008 Updated study design, study control, and descriptor, from Roche record.